Halo Biosciences

Halo Biosciences is a biotechnology startup based in the United States, founded in 2019. The company is dedicated to Advancing development of a new pathway for pulmonary hypertension and interstitial lung disease through the creation of first-in-class, disease-modifying therapies. Halo's innovative approach focuses on editing the extracellular matrix (ECM) to exploit novel insights in ECM biology, selectively editing its components to restore homeostasis in diseases affected by inflammation and fibrosis. The startup's lead program aims to deliver a first-in-class disease-modifying therapy for pulmonary hypertension. As of now, there is no record of last investment and the identity of last investment investors.